Syncona Limited (LSE:SYNC) is alife-scienceInvestmentcompanyfocused on building and investing in healthcare businesses with the potential to develop innovative medicines and technologies.
Allergy Therapeutics plc is an international commercial biotechnology company specialising in allergy immunotherapy. It sells proprietary and third-party products across European markets while developing next-generation treatments for pollen and food allergies. The recent share-price increase reflects accelerating commercial growth, the launch of Grassmuno and …
Cambridge Cognition Holdings Plc provides digital cognitive assessment technology used primarily in pharmaceutical clinical trials and healthcare research to measure memory, attention and other cognitive functions. Its shares are gaining as the market reassesses demand for its CANTAB platform amid continued pharmaceutical industry investment …
Genflow Biosciences Plc is a clinical-stage biotechnology company focused on developing gene-based therapies targeting biological pathways associated with ageing and age-related disease. Its shares are advancing amid renewed investor interest in longevity science, a research area that has attracted growing attention from both specialist …
HemoGenyx Pharmaceuticals Plc is a clinical-stage biopharmaceutical company developing treatments for blood cancers and autoimmune diseases. Its lead programme, HG-CT-1, is a proprietary CAR-T therapy targeting relapsed or refractory acute myeloid leukaemia. The latest share-price strength reflects progress from scientific development toward potential clinical …
ValiRx LSE:VAL has moved sharply into focus after gaining6.25% on 11 August 2026, with investor attention centred on fresh progress around its cancer-treatment pipeline.
Verici Dx LSE:VRCI has attracted renewed investor attention after gaining11.11% on 11 August 2026.
Proteome Sciences LSE:PRM has attracted renewed investor attention after its shares gained8.59% on 11 August 2026.
Futura Medical LSE:FUM has attracted renewed market attention after its shares advanced13.24% on 11 August 2026.
Verici DxLSE:VRCIdeclined11.11% on 11 August 2026, creating an interesting disconnect between the share-price performance and the company's latest operational announcement.